Healthcare
Live Price
Offline$1.43
+4.38% today
1Y Change
-91.98%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VolitionRx Limited (VNRX) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $1.43 and down 92.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +40.0%, EPS growth of +29.0%, a dividend yield of 0.0%. What stands out right now is revenue +40.0%, EPS +29.0%, free cash flow +25.3% with operating margin -1253.4% and ROIC 1261.8%. Valuation sits in the middle of the pack at price/sales 7.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VNRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VNRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VNRX Max Drawdown
-92.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VNRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$90.0K
-70.6% YoY
FY Net Income
-$26.8M
+11.4% YoY
Free Cash Flow
-$21.8M
-29.6% YoY
Revenue Growth
+40.0%
EPS Growth
+29.0%
Gross Margin
100.0%
Net Margin
-1352.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 1M | 775K | 306K | 90K |
| Gross Profit | 2M | 1M | 775K | 306K | 90K |
| Operating Income | -21M | -27M | -36M | -32M | -28M |
| EBITDA | -20M | -26M | -34M | -29M | -26M |
| Net Income | -23M | -27M | -35M | -30M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 3M | 21M | 11M | 21M |
| Total Assets | 7M | 9M | 28M | 18M | 27M |
| Total Liabilities | 42M | 36M | 37M | 21M | 10M |
| Shareholder Equity | -34M | -25M | -8M | -3M | 18M |
| Total Debt | 11M | 6M | 6M | 5M | 4M |
| Net Debt | 10M | 3M | -15M | -6M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21M
-36.5% YoY
Capital Expenditures
974K
+38.0% YoY
Free Cash Flow
22M
-29.6% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-1253.4%
Net Margin
-1352.2%
ROE
72.7%
Debt / Equity
-0.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.